Cost-Utility of Ranibizumab Versus Aflibercept for Treating Visual Impairment Due to Diabetic Macular Edema In Greece
Nov 1, 2015, 00:00
10.1016/j.jval.2015.09.568
https://www.valueinhealthjournal.com/article/S1098-3015(15)02644-3/fulltext
Title :
Cost-Utility of Ranibizumab Versus Aflibercept for Treating Visual Impairment Due to Diabetic Macular Edema In Greece
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(15)02644-3&doi=10.1016/j.jval.2015.09.568
First page :
A423
Section Title :
Research Podium Presentations - Session 1 and Session 2
Open access? :
No
Section Order :
485